Validation of high gradient magnetic field based drug delivery to magnetizable implants under flow

Validation of high gradient magnetic field based drug delivery to magnetizable implants under flow
复制标题

DOI:
10.1109/tbme.2007.899347
复制
发表时间:
2008-02-01
影响因子:
4.6
通讯作者:
Friedman, Gary
Friedman, Gary
中科院分区:
工程技术2区
文献类型:
--
作者:
Forbes, Zachary G.;Yellen, Benjamin B.;Friedman, Gary

文献摘要

被引文献

相似文献

药物洗脱支架晚期血栓形成的发生率越来越高,需要新的策略来干预冠状动脉疾病。本文展示了我们的微创,靶向给药系统,使用诱导磁性管理可重复的和患者特定剂量的治疗剂在人体的特定部位的进一步发展。我们的第一个目标是使用可磁化支架预防和治疗冠状动脉再狭窄;然而,未来的应用包括靶向肿瘤、血管缺损和其他局部病变。未来剂量可通过静脉注射给予相同部位。这种基于植入物的药物递送系统通过将弱磁化支架或植入物放置在心血管系统中的精确位置,然后递送磁敏感药物载体来起作用。支架能够在体内施加高局部磁场梯度,同时仅将身体暴露于适度的外部场。血管内产生的局部梯度产生了吸引和保持植入部位处的含药物磁性纳米颗粒所需的力。一旦这些颗粒被捕获,它们就能够递送治疗剂。例如抗塑料、放射性或生物细胞。
The drug-eluting stent's increasingly frequent occurrence late stage thrombosis have created a need for new strategies for intervention in coronary artery disease. This paper demonstrates further development of our minimally invasive, targeted drug delivery system that uses induced magnetism to administer repeatable and patient specific dosages of therapeutic agents to specific sites in the human body. Our first, aim is the use of magnetizable stents for the prevention and treatment of coronary restenosis; however, future applications include the targeting of tumors, vascular defects, and other localized pathologies. Future doses can be administered to the same site by intravenous injection. This implant-based drug delivery system functions by placement of a weakly magnetizable stent or implant at precise locations in the cardiovascular system, followed by the delivery of magnetically susceptible drug carriers. The stents are capable of applying high local magnetic field gradients within the body, while only exposing the body to a modest external field. The local gradients created within the blood vessel create the forces needed to attract and hold drug-containing magnetic nanoparticles at the implant site. Once these particles are captured, they are capable of delivering therapeutic agents. such as antineoplastics, radioactivity, or biological cells.